This article was reviewed by member(s) of WikiProject Articles for creation. The project works to allow users to contribute quality articles and media files to the encyclopedia and track their progress as they are developed. To participate, please visit the project page for more information.Articles for creationWikipedia:WikiProject Articles for creationTemplate:WikiProject Articles for creationAfC articles
This article is within the scope of WikiProject California, a collaborative effort to improve the coverage of the U.S. state of California on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CaliforniaWikipedia:WikiProject CaliforniaTemplate:WikiProject CaliforniaCalifornia articles
This article is within the scope of WikiProject Organizations, a collaborative effort to improve the coverage of Organizations on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.OrganizationsWikipedia:WikiProject OrganizationsTemplate:WikiProject Organizationsorganization articles
The following Wikipedia contributors may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.
The following is unsourced and was moved here per WP:PRESERVE. Per WP:BURDEN please do not restore without finding independent, reliable sources, checking the content against them, and citing them, and ensuring that this content has appropriate WP:WEIGHT in the article overall.
Dr. Nelson was CEO from 2010 until July 2013. During that time, the Epic team industrialized the academic technology from the Kuhn lab, established numerous academic collaborations (Memorial Sloan Kettering, Moffitt, MD Anderson, Royal Marsden, Yale etc.), received multiple grants from the National Cancer Institute, signed collaborations with over 10 pharmaceutical companies for many clinical studies including over 3000 patients, closed two rounds of private equity financing with top tier investors (Domain Associates, Roche, and Pfizer), executed a partnership with LabCorp to provide global reach, partnered with Microsoft to provide innovative and scalable computational solutions, and initiated a business strategy to pursue both independent diagnostic products as well as companion diagnostics with its pharmaceutical partners.
